A detailed history of Adar1 Capital Management, LLC transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Adar1 Capital Management, LLC holds 31,509 shares of JANX stock, worth $1.13 Million. This represents 0.34% of its overall portfolio holdings.

Number of Shares
31,509
Previous 13,000 142.38%
Holding current value
$1.13 Million
Previous $591 Million 185.65%
% of portfolio
0.34%
Previous 0.1%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 13, 2025

BUY
$40.18 - $66.83 $743,691 - $1.24 Million
18,509 Added 142.38%
31,509 $1.69 Billion
Q3 2024

Nov 14, 2024

BUY
$35.29 - $50.26 $180,296 - $256,778
5,109 Added 64.74%
13,000 $591 Million
Q2 2024

Aug 13, 2024

SELL
$35.12 - $64.78 $214,548 - $395,741
-6,109 Reduced 43.64%
7,891 $331 Million
Q1 2024

May 15, 2024

BUY
$7.93 - $49.75 $111,020 - $696,500
14,000 New
14,000 $527 Million

Others Institutions Holding JANX

About Janux Therapeutics, Inc.


  • Ticker JANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,663,000
  • Market Cap $1.5B
  • Description
  • Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...
More about JANX
Track This Portfolio

Track Adar1 Capital Management, LLC Portfolio

Follow Adar1 Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adar1 Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Adar1 Capital Management, LLC with notifications on news.